Business Wire

  1. Altasciences And WuXi AppTec Enter Into Collaboration For WIND Projects

    Altasciences, a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development from lead candidate selection to proof of concept, announced today that they have entered into an agreement to support WuXi AppTec’s Investigational New Drug (WIND) platform. WIND combines world-class CRO services with cross-functional program management and global regulatory expertise to support IND applications. WuXi Clinical, the clinical CRO arm of WuXi AppTec, will be responsible for managing

  2. Exelixis And Iconic Therapeutics Enter Into Exclusive Option And License Agreement For Novel Antibody-Drug Conjugate Program

    Exelixis, Inc. recently announced that it has entered into an exclusive option and license agreement with Iconic Therapeutics, Inc. (Iconic), a private biopharmaceutical company focused on cancer and retinal disease, to advance an innovative next-generation antibody-drug conjugate (ADC) program for cancer

  3. Vertex And Kymera Therapeutics Establish Strategic Collaboration To Discover And Develop Targeted Protein Degradation Medicines For Serious Diseases

    Vertex Pharmaceuticals Incorporated and Kymera Therapeutics recently announced that the two companies have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets

  4. BioCompute And WHISE-Embleema Launch Framework For FDA Drug Submissions

    BioCompute, a collaboration between The George Washington University and the FDA to improve communication of bioinformatics pipelines, recently announced a new guidance for life sciences companies using next generation sequencing (NGS) analysis as part of the regulatory approval process

  5. FDA Grants Orphan Drug Designation To Ayala’s AL101 For Potential Treatment Of Adenoid Cystic Carcinoma (ACC)

    Ayala Pharmaceuticals, a clinical-stage company developing medicines for cancers that are genetically defined, announced recently that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) for AL101, a potent and selective inhibitor of gamma secretase-mediated Notch signalling, for the treatment of ACC

  6. Adimab Announces Multi-Target Expansion For The Discovery Of Antibodies With Another Global Pharma Partner

    Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced the expansion of an earlier partnership with Novartis

  7. Arcus Biosciences And Strata Oncology Announce Clinical Development Collaboration For Anti-PD-1 Antibody AB122

    Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Strata Oncology, Inc. (“Strata”), a precision oncology company, recently announced that the companies have entered into a clinical development collaboration utilizing Strata’s precision drug development platform and proprietary biomarkers to evaluate AB122, Arcus’s clinical-stage anti-PD-1 antibody, in a basket trial including tumor types that are generally not responsive to anti-PD-1 therapy

  8. Invicro And iThera Medical Announce A Strategic Partnership To Enhance In Vivo Imaging Capabilities With The MSOT inVision Optoacoustic Imaging Platform

    Invicro LLC, a Konica Minolta company and iTheraMedical GmbH announced a unique partnership with the placement of the MSOT inVision platform in Invicro’s in vivo laboratory out of its Boston headquarters

  9. AVROBIO, Inc. Announces FDA Clearance Of Investigational New Drug Application For AVR-RD-01 Gene Therapy For The Treatment Of Fabry Disease

    AVROBIO, Inc. (the “Company”), a Phase 2 clinical-stage gene therapy company, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AVR-RD-01, its gene therapy candidate for the treatment of Fabry disease

  10. Allegro Ophthalmics Expands Its Anti-Integrin Portfolio With New Front-Of-The-Eye Drug Candidate ALG-1007 For The Treatment Of Dry Eye Disease

    Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, recently announced the expansion of the company’s anti-integrin portfolio with the new front-of-the-eye-drug candidate ALG-1007